A non-synonymous single nucleotide polymorphism in SIRT6 predicts neurological severity in Friedreich ataxia

• Published in: Frontiers in molecular biosciences Vol. 9; p. 933788
• Main Authors: Rodden, Layne N., Rummey, Christian, Dong, Yi Na, Lagedrost, Sarah, Regner, Sean, Brocht, Alicia, Bushara, Khalaf, Delatycki, Martin B., Gomez, Christopher M., Mathews, Katherine, Murray, Sarah, Perlman, Susan, Ravina, Bernard, Subramony, S. H., Wilmot, George, Zesiewicz, Theresa, Bolotta, Alessandra, Domissy, Alain, Jespersen, Christine, Ji, Baohu, Soragni, Elisabetta, Gottesfeld, Joel M., Lynch, David R.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 05.09.2022
• Subjects: ataxia; clinical trial; mitochondrion; modifier; Molecular Biosciences; mRNA profiling; SIRT6
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2022.933788

Introduction: Friedreich ataxia (FRDA) is a recessive neurodegenerative disease characterized by progressive ataxia, dyscoordination, and loss of vision. The variable length of the pathogenic GAA triplet repeat expansion in the FXN gene in part explains the interindividual variability in the severity of disease. The GAA repeat expansion leads to epigenetic silencing of FXN; therefore, variability in properties of epigenetic effector proteins could also regulate the severity of FRDA. Methods: In an exploratory analysis, DNA from 88 individuals with FRDA was analyzed to determine if any of five non-synonymous SNPs in HDAC s/ SIRT s predicted FRDA disease severity. Results suggested the need for a full analysis at the rs352493 locus in SIRT6 ( p .Asn46Ser). In a cohort of 569 subjects with FRDA, disease features were compared between subjects homozygous for the common thymine SIRT6 variant (TT) and those with the less common cytosine variant on one allele and thymine on the other (CT). The biochemical properties of both variants of SIRT6 were analyzed and compared. Results: Linear regression in the exploratory cohort suggested that an SNP (rs352493) in SIRT6 correlated with neurological severity in FRDA. The follow-up analysis in a larger cohort agreed with the initial result that the genotype of SIRT6 at the locus rs352493 predicted the severity of disease features of FRDA. Those in the CT SIRT6 group performed better on measures of neurological and visual function over time than those in the more common TT SIRT6 group. The Asn to Ser amino acid change resulting from the SNP in SIRT6 did not alter the expression or enzymatic activity of SIRT6 or frataxin, but iPSC-derived neurons from people with FRDA in the CT SIRT6 group showed whole transcriptome differences compared to those in the TT SIRT6 group. Conclusion: People with FRDA in the CT SIRT6 group have less severe neurological and visual dysfunction than those in the TT SIRT6 group. Biochemical analyses indicate that the benefit conferred by T to C SNP in SIRT6 does not come from altered expression or enzymatic activity of SIRT6 or frataxin but is associated with changes in the transcriptome.